Table 2.
Glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and cytochrome P450 2D6 (CYP2D6) genotype and activity scores among RDT-positive participants screened and randomized; n (%)
| Total RDT positives screened [n = 181] | Randomized to primaquine [n = 70] | Not randomized to primaquine [n = 70] | |
|---|---|---|---|
| G6PD variant genotype | |||
| A− | 24 (14.0) | 11 (16.7) | 6 (9.0) |
| A+ | 38 (22.1) | 9 (13.6) | 17 (25.4) |
| B | 110 (64.0) | 46 (69.7) | 44 (65.7) |
| G6PD phenotype (U/dL) | 73 (51–91) | 68 (51–89) | 74 (40–90) |
| CYP2D6 variant genotype (activity score, ASa) | |||
| *1/*1 (AS 2.0; EM) | 129 (74.4) | 48 (71.6) | 49 (74.2) |
| *1/*10 (AS 1.5; EM) | 13 (7.6) | 5 (7.5) | 5 (7.6) |
| *1/*17 (AS 1.5; EM) | 18 (10.5) | 8 (11.9) | 8 (12.1) |
| *1/*4 (AS 1.0; IM) | 1 (0.6) | 1 (1.5) | 0 (0) |
| *10/*17 (AS 1.0; IM) | 3 (1.8) | 2 (3.0) | 0 (0) |
| *17/*17 (AS 1.0; IM) | 4 (2.3) | 2 (3.0) | 2 (3.0) |
| *4/*10 (AS 0.5; IM) | 1 (0.6) | 0 (0) | 1 (1.5) |
| *4/*10/*17 (AS 1.0; IM) | 2 (1.2) | 1 (1.5) | 1 (1.5) |